# A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

Study · id `cardio:ct-nct07187115` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07187115](<https://clinicaltrials.gov/study/NCT07187115>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07187115

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 699 participants.

## Technical summary

Registry record NCT07187115. Randomized; no masking; primary purpose treatment. Start 2025-11-07 (actual); primary completion 2027-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 699 participants (planned count; ClinicalTrials.gov record NCT07187115, source copy `cardio:ctgov-nct07187115-2026-10-23`, retrieved 2026-10-26)
- Started: 2025-11-07 (actual) (ClinicalTrials.gov record NCT07187115, source copy `cardio:ctgov-nct07187115-2026-10-23`, retrieved 2026-10-26)
- Primary completion: 2027-01 (anticipated) (ClinicalTrials.gov record NCT07187115, source copy `cardio:ctgov-nct07187115-2026-10-23`, retrieved 2026-10-26)
- Completion: 2027-01 (anticipated) (ClinicalTrials.gov record NCT07187115, source copy `cardio:ctgov-nct07187115-2026-10-23`, retrieved 2026-10-26)
- Countries: United States; Belgium; Hong Kong SAR China; Spain (ClinicalTrials.gov record NCT07187115, source copy `cardio:ctgov-nct07187115-2026-10-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07187115-2026-10-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
- Acronym: OPTIMIZE
- Condition: Atrial Fibrillation (AF)
- Condition: Persistant Atrial Fibrillation
- Intervention (Device): FARAPOINT Pulsed Field Ablation System
- Intervention (Device): OptiMap System (non-ablative)
- Intervention (Device): FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: 595784abf519748726a11777fdc26e03c87a245f8b0480b50cbb44672373fb7c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
